Skip to content

Study · Observational study · n = 26 · 2015

5 results

Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.

Giagulli VA, Carbone MD, Ramunni MI, Licchelli B, De Pergola G, Sabbà C, Guastamacchia E, Triggiani V

Andrology7 Oct 2015Cited by 80 (Europe PMC)

PMID26447645 (opens in a new tab)DOI10.1111/andr.12099 (opens in a new tab)PepBankPUB-26447645
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In obese, diabetic, hypogonadal men with erectile dysfunction, adding liraglutide to testosterone and metformin in poor responders allowed the HbA1c target to be reached.

    In plain wordsIn obese men with type 2 diabetes and low testosterone, adding liraglutide to their treatment was linked to reaching the HbA1c target.

    Peptide
    Liraglutide
    Outcome
    DecreaseGlycaemic target (HbA1c below 7.5%)
    Study

    n = 26

    Comparator
    Same patients before liraglutide was added (T2)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 μg/day · 1 yearAs given in this study (human).

    Measurements

    HbA1c target reached
    < 7.5%
    G1N and G2N

    Source sentences

    Summary
    L added to TU and Met regimen in G1N and G2N allowed these patients to reach not only the glycaemic target [HbA1c = <7.5% (<58 nmol/mol)]
    2 context sentences
    Summary · context
    Forty-three obese, diabetic and hypogonadal men (aged 45-59 years) were evaluated because of complaining about the recent onset of ED.
    Summary · context
    In the poor responders (N) to this therapy in terms of glycaemic target (G1N: n = 16; G2N: n = 10), liraglutide (L) (1.2 μg/day) was added for a second year, while the good responders (Y) to T + Met (G1Y: 14/30 and G2Y: 3/13) continued this two drugs regimen therapy for another year.
  2. 02HumanObservational studyEfficacy outcome

    In obese, diabetic, hypogonadal men with erectile dysfunction, adding liraglutide to testosterone and metformin in poor responders significantly reduced body weight.

    In plain wordsIn obese men with type 2 diabetes and low testosterone, adding liraglutide to their treatment was linked to lower body weight.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight
    Study

    n = 26

    Comparator
    Same patients before liraglutide was added (T2)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.2 μg/day · 1 yearAs given in this study (human).

    Source sentences

    Summary
    L added to TU and Met regimen in G1N and G2N allowed these patients to reach not only the glycaemic target [HbA1c = <7.5% (<58 nmol/mol)] and a significant reduction in body weight (p < 0.01)
    2 context sentences
    Summary · context
    Forty-three obese, diabetic and hypogonadal men (aged 45-59 years) were evaluated because of complaining about the recent onset of ED.
    Summary · context
    In the poor responders (N) to this therapy in terms of glycaemic target (G1N: n = 16; G2N: n = 10), liraglutide (L) (1.2 μg/day) was added for a second year, while the good responders (Y) to T + Met (G1Y: 14/30 and G2Y: 3/13) continued this two drugs regimen therapy for another year.
  3. 03HumanObservational studyEfficacy outcome

    In obese, diabetic, hypogonadal men with erectile dysfunction, adding liraglutide to testosterone and metformin in poor responders further increased SHBG.

    In plain wordsIn obese men with type 2 diabetes and low testosterone, adding liraglutide was linked to a further rise in sex hormone binding globulin.

    Peptide
    Liraglutide
    Outcome
    IncreaseSerum SHBG
    Study

    n = 26

    Comparator
    Same patients before liraglutide was added (T2)
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1.2 μg/day · 1 yearAs given in this study (human).

    Source sentences

    Summary
    a further increase in SHBG (p < 0.05) and T (p < 0.01) plasma levels
    2 context sentences
    Summary · context
    Forty-three obese, diabetic and hypogonadal men (aged 45-59 years) were evaluated because of complaining about the recent onset of ED.
    Summary · context
    In the poor responders (N) to this therapy in terms of glycaemic target (G1N: n = 16; G2N: n = 10), liraglutide (L) (1.2 μg/day) was added for a second year, while the good responders (Y) to T + Met (G1Y: 14/30 and G2Y: 3/13) continued this two drugs regimen therapy for another year.
  4. 04HumanObservational studyEfficacy outcome

    In obese, diabetic, hypogonadal men with erectile dysfunction, adding liraglutide to testosterone and metformin in poor responders further increased testosterone levels.

    In plain wordsIn obese men with type 2 diabetes and low testosterone, adding liraglutide to their treatment was linked to a further rise in testosterone levels.

    Peptide
    Liraglutide
    Outcome
    IncreaseTotal testosterone
    Study

    n = 26

    Comparator
    Same patients before liraglutide was added (T2)
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1.2 μg/day · 1 yearAs given in this study (human).

    Source sentences

    Summary
    a further increase in SHBG (p < 0.05) and T (p < 0.01) plasma levels
    2 context sentences
    Summary · context
    Forty-three obese, diabetic and hypogonadal men (aged 45-59 years) were evaluated because of complaining about the recent onset of ED.
    Summary · context
    In the poor responders (N) to this therapy in terms of glycaemic target (G1N: n = 16; G2N: n = 10), liraglutide (L) (1.2 μg/day) was added for a second year, while the good responders (Y) to T + Met (G1Y: 14/30 and G2Y: 3/13) continued this two drugs regimen therapy for another year.
  5. 05HumanObservational studyEfficacy outcome

    In obese, diabetic, hypogonadal men with erectile dysfunction, adding liraglutide to testosterone and metformin in poor responders significantly increased the IIEF score.

    In plain wordsIn obese men with type 2 diabetes and low testosterone, adding liraglutide to their treatment was linked to higher erectile function scores.

    Peptide
    Liraglutide
    Outcome
    IncreaseIIEF score
    Study

    n = 26

    Comparator
    Same patients before liraglutide was added (T2)
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    1.2 μg/day · 1 yearAs given in this study (human).

    Source sentences

    Summary
    a significant increment of IIEF score (T3).
    2 context sentences
    Summary · context
    Forty-three obese, diabetic and hypogonadal men (aged 45-59 years) were evaluated because of complaining about the recent onset of ED.
    Summary · context
    In the poor responders (N) to this therapy in terms of glycaemic target (G1N: n = 16; G2N: n = 10), liraglutide (L) (1.2 μg/day) was added for a second year, while the good responders (Y) to T + Met (G1Y: 14/30 and G2Y: 3/13) continued this two drugs regimen therapy for another year.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.